Yoshihiko Hatanaka, President and Chief Executive Officer of Astellas commented, "The sale of Prosidion’s DPP-IV patent estate and royalty stream supports our strategic goal of maximizing value for Astellas’ shareholders. The sale of this large, passive, non-core financial asset will free up capital for reinvestment in strategic initiatives. We are pleased to have been able to work with Royalty Pharma in this important transaction."

NESINA® is a once-daily pill that is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes.

People with diabetes mellitus have a deficiency or absence of a hormone produced by the pancreas, called insulin. Insulin is the main hormone responsible for the control of sugar (glucose) in the blood. In type 2 diabetes the pancreas does not produce sufficient insulin, and the cells of the body are resistant to the low levels of insulin circulating in the blood. Insulin would normally make the cells remove sugar from the blood; hence in type 2 diabetes blood sugar levels can rise too high.

NESINA® is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors work by increasing the amounts of certain natural substances, thereby enhancing the body’s inherent ability to control blood sugar levels.

Therapeutic Area


Acquisition Date

Jun 2011